PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30888847-4	2019	Acetylsalicylic acid (ASA; also known as aspirin) is known to irreversibly inhibit COX-1, thereby blocking AA-mediated signaling; however, it is unclear whether ASA use alters growth factor release from freshly isolated PRP.	Aspirin	22-25	complement component 4 binding protein alpha	Homo sapiens	220-223	
30888847-5	2019	PURPOSE:: To assess the effects of low-dose ASA use on activation of growth factor release from freshly isolated human PRP via AA and thrombin (TBN).	Aspirin	44-47	complement component 4 binding protein alpha	Homo sapiens	119-122	
30888847-17	2019	CONCLUSION:: Daily use of low-dose ASA reduces VEGF, PDGF-AB, and TGF-beta1 expression in freshly isolated human LR-PRP when activated with AA.	Aspirin	35-38	complement component 4 binding protein alpha	Homo sapiens	116-119	
30888847-18	2019	CLINICAL RELEVANCE:: Reduction in growth factor release attributed to daily use of low-dose ASA or other COX inhibitors can be mitigated when PRP samples are activated with TBN.	Aspirin	92-95	complement component 4 binding protein alpha	Homo sapiens	142-145	
18775097-5	2009	ASA and HT-AC had a greater effect in whole blood than in PRP when ADP or collagen was used as inducer.	Aspirin	0-3	complement component 4 binding protein alpha	Homo sapiens	58-61	
21688846-4	2011	Consequent on ASA release, the compounds were capable of inhibiting collagen-induced platelet aggregation of human platelet-rich plasma (PRP).	Aspirin	14-17	complement component 4 binding protein alpha	Homo sapiens	115-135	
21688846-4	2011	Consequent on ASA release, the compounds were capable of inhibiting collagen-induced platelet aggregation of human platelet-rich plasma (PRP).	Aspirin	14-17	complement component 4 binding protein alpha	Homo sapiens	137-140	
18775097-6	2009	ASA and HT-AC had a greater effect in PRP+leucocytes than in PRP alone.	Aspirin	0-3	complement component 4 binding protein alpha	Homo sapiens	38-41	
18775097-6	2009	ASA and HT-AC had a greater effect in PRP+leucocytes than in PRP alone.	Aspirin	0-3	complement component 4 binding protein alpha	Homo sapiens	61-64	
16015412-2	2005	Aspirin also inhibits thrombin generation (TG) in platelet-rich plasma (PRP) activated by sodium arachidonate (AA).	Aspirin	0-7	complement component 4 binding protein alpha	Homo sapiens	72-75	
3012375-5	1986	After cyclo-oxygenase blockade by acetylsalicylic acid (ASA), PRP was stimulated by a supramaximal concentration of PAF.	Aspirin	34-54	complement component 4 binding protein alpha	Homo sapiens	62-65	
3012375-5	1986	After cyclo-oxygenase blockade by acetylsalicylic acid (ASA), PRP was stimulated by a supramaximal concentration of PAF.	Aspirin	56-59	complement component 4 binding protein alpha	Homo sapiens	62-65	
8864252-8	1996	After adjustment for age, C4bp levels increased significantly with increasing ASL and ASA.	Aspirin	86-89	complement component 4 binding protein alpha	Homo sapiens	26-30	
33895438-7	2021	RESULTS: The generation of platelet aggregates under flow was significantly increased by the pretreatment of PRP with 100-200 ng/mL C6O4, compared to both the control condition and the experiment performed in presence of ASA.	Aspirin	221-224	complement component 4 binding protein alpha	Homo sapiens	109-112